Fully funded pipeline in advanced stages. 30% short interest?Ocugen IncBATS:OCGNEhrlichmanINTRODUCTION: - The company has three compounds in the pipeline, two of which are slated for commercial launch by 2028, with the third one soon to follow. - The business if fully funded towards those goals as of the writing of this idea. - The two compounds in Phase 3 studies are already showing significant promise, as reflected in the EU and US regulatory designations: Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug Designation (ODD), Orphan Medicinal Product Designation (OMPD), Advance Therapy Medicinal Products (ATMP), Rare Pediatric Disease Designation (RPDD). And yet the company is shorted 30% of its float. Roughly 100 million shares are shorted. This appears to be a recipe for disaster (for the shorts), especially since the chart appears to be notably bullish. THE TA: The above 3D chart illustrates the main bullish arguments in this idea. 1. The company is out of a multi-year downtrend which started with the IPO in 2015. 2. Following a massive spike in 2021, price action entered a three-year period of distribution (rotated teal rectangle). 3. The distribution period ended with a breakout of the multi-year downtrend. 4. The breakout from the multi-year downtrend precipitated a period of uptrending consolidation under the $1.75 resistance. 5. The $1.75 resistance together with higher lows that have been printing since November 2023 create an ascending triangle, a classic bullish continuation pattern. 6. Price action has exited a local corrective downtrend (light red diagonal channel) just as a double bottom and a potential new higher low have printed on the following: - top of market structure (the horizontal support/resistance channel); three times tested now, - the golden ratio; following a retracement from a previous local high (the 0.382 lies squarely on top of market structure), - the bottom of a 3D Gaussian Channel - the 200-day SMA (which happens to run exactly along the bottom of the 3D Gaussian Channel). 7. RSI and MFI are both out of local corrective downtrends (MFI with backtest). SUPPLEMENTAL TA: 1. On the 6D chart, price action confirms support on GC mean just as the 50-day and 200-day SMAs are gearing up for a life-cross, first time ever: 2. On the 13D chart, price action prints a successful test of support on past horizontal resistance (and a potential new local higher low) just as the 13D GC flips from red to green for the first time ever: MFI and RSI on this timeframe have both printed higher lows. Stochastic RSI is gearing up for a cross up 20 which should be a favorable event like most of the past ones, given all the other bullish signals. SUMMARY: This is the kind of bio I'm looking for these days (having learned to do so the hard way). Although not as overwhelmingly bullish as some ( ALT for example) it's got all the important green lights on: a bullish chart, funded for at least 2 years, and a pipeline with very promising compounds in Phase 3 of trials. This should minimize the risk of downside from the typical troubles that plague startup bios: failed trials and no money. Dashed horizontal lines in light blue denote major levels of support/resistance. If or when the $1.75 resistance is conquered, there is very little to stop the action before $7, and then $14. Should that break too, I wouldn't push my luck past $30. I'm not using a stop-loss. *** Written by hand. I'm not a pro. I write these down for myself so triple-check it all if you think of jumping in after me. Or just triple-check it anyway to rub an error in my face, if I've made one. I'll own it, and hopefully learn from it.